SCHEMBL4263471

SCHEMBL4263471

NCC(N)S(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.55
CA1 P00915 1/20 0.55
CA9 Q16790 1/20 0.55
SCN1A P35498 2/20 0.47
SCN2A Q99250 2/20 0.47
SCN3A Q9NY46 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAOA P21397 1/20 0.47
LOX P28300 1/20 0.47
F2 P00734 3/20 0.46
PRSS1 P07477 3/20 0.46
PRSS2 P07478 3/20 0.46
PRSS3 P35030 3/20 0.46
HTR6 P50406 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117507 0.82 CYP3A4 (0.58) KDM4ECYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL27403973 0.79 CA1 (0.58) CA2CA1CA9SCN1ASCN2A
SCHEMBL27207049 0.79 CA1 (0.46) CA2CA1CA9SCN1ASCN2A
SCHEMBL1195872 0.78 TTR (0.42) ALDH1A1CYP3A4HSD17B10KEAP1NFE2L2
SCHEMBL7431903 0.78 SLC1A3 (0.50) CA2CA1CA9SCN1ASCN2A
SCHEMBL1195870 0.76 CA2 (0.60) CA2KDM4ECYP1A2CYP2C19HSD17B10
SCHEMBL27207228 0.76 CA1 (0.44) CA2CA1CA9SCN1ASCN2A
SCHEMBL8648359 0.76 CA1 (0.55) CA2CA1CA9SCN1ASCN2A
SCHEMBL6572028 0.75 SLC1A3 (0.57) CA2CA1CA9ALDH1A1F2
SCHEMBL3245449 0.74 CA1 (0.57) CA2CA1CA9F2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605146-B2 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2009-10-20 US claimed
US-20020077456-A1 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2002-06-20 US claimed
EP-1199312-A2 Process for producing an amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-24 EP claimed
US-7605146-B2 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2009-10-20 US disclosed
US-20020077456-A1 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2002-06-20 US disclosed
EP-1199312-A2 Process for producing an amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077456-A1 Process for producing an amide compound NAAA, ACMSD, CPS1 CA2 1391/4885CA1 286/4885CA9 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.